Novel targets to treat airway fibrosis

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1026880

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Airway fibrosis or scaring causes significant morbidity in both chronic obstructive pulmonary disease (COPD) and asthma . These diseases affect 10-15% of the population, and cost the health system $1.15 billion per year. Airway fibrosis is not decreased by the current therapeutics used to treat COPD and asthma, and as such there is a pressing need to develop therapeutics to specifically treat airway fibrosis. Dr Brian Oliver has partnered with Pharmaxis to develop new therapeutics to specifically treat fibrosis

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2015

Funding Scheme: Career Development Fellowships

Funding Amount: $422,685.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Respiratory Diseases

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

airway fibrosis | asthma | asthma severity | chronic obstructive pulmonary disease (COPD) | fibrosis

Related Links